Adoptive T-cell therapy for Hodgkin lymphoma.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
26 10 2021
26 10 2021
Historique:
received:
28
06
2021
accepted:
01
09
2021
pubmed:
6
10
2021
medline:
3
11
2021
entrez:
5
10
2021
Statut:
ppublish
Résumé
Although CAR T-cell therapy is US Food and Drug Administration-approved for B-cell non-Hodgkin lymphomas, the development of adoptive immunotherapy for the treatment of classic Hodgkin lymphoma (cHL) has not accelerated at a similar pace. Adoptive T-cell therapy with Epstein-Barr virus-specific cytotoxic T lymphocytes and CD30 CAR T cells have demonstrated significant clinical responses in early clinical trials of patients with cHL. Additionally, CD19 and CD123 CAR T cells that target the immunosuppressive tumor microenvironment in cHL have also been investigated. Here we discuss the landscape of clinical trials of adoptive immunotherapy for patients with cHL with a view toward current challenges and novel strategies to improve the development of CAR T-cell therapy for cHL.
Identifiants
pubmed: 34610100
pii: 477174
doi: 10.1182/bloodadvances.2021005304
pmc: PMC8945637
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4291-4302Subventions
Organisme : NCI NIH HHS
ID : K99 CA212302
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA214278
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA212302
Pays : United States
Informations de copyright
© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Clin Cancer Res. 2017 Mar 1;23(5):1156-1166
pubmed: 27582488
Blood. 2005 Jun 15;105(12):4677-84
pubmed: 15713795
Am J Pathol. 1999 Jun;154(6):1685-91
pubmed: 10362793
Cancer. 2004 May 1;100(9):1892-901
pubmed: 15112270
Blood. 2018 Nov 29;132(22):2351-2361
pubmed: 30262660
J Clin Oncol. 2005 Jul 20;23(21):4634-42
pubmed: 15837968
Clin Cancer Res. 2012 Mar 15;18(6):1611-8
pubmed: 22271878
Cytotherapy. 2019 Feb;21(2):212-223
pubmed: 30396848
Blood. 1996 Apr 1;87(7):2918-29
pubmed: 8639912
Blood. 2010 Feb 4;115(5):925-35
pubmed: 19880495
Cancers (Basel). 2018 Jun 11;10(6):
pubmed: 29891791
Blood. 2017 Nov 30;130(22):2420-2430
pubmed: 28893733
Cancer Discov. 2020 Mar;10(3):406-421
pubmed: 31857391
N Engl J Med. 2010 Aug 12;363(7):640-52
pubmed: 20818855
J Clin Invest. 2017 Sep 1;127(9):3462-3471
pubmed: 28805662
N Engl J Med. 2018 Jan 25;378(4):331-344
pubmed: 29224502
N Engl J Med. 2010 Nov 4;363(19):1812-21
pubmed: 21047225
J Clin Oncol. 2013 Feb 20;31(6):684-91
pubmed: 23182987
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
Lancet. 2015 May 9;385(9980):1853-62
pubmed: 25796459
Blood. 2009 Feb 12;113(7):1581-8
pubmed: 18974373
Br J Haematol. 2004 Mar;124(5):645-52
pubmed: 14871252
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Blood. 2016 Sep 22;128(12):1562-6
pubmed: 27432875
Oncoimmunology. 2017 Mar 3;6(4):e1295202
pubmed: 28507804
J Exp Med. 2004 Dec 20;200(12):1623-33
pubmed: 15611290
Blood. 2009 Jun 4;113(23):5920-6
pubmed: 19188663
J Clin Oncol. 2007 Jul 20;25(21):3101-8
pubmed: 17536082
Blood Rev. 2004 Sep;18(3):193-209
pubmed: 15183903
Nat Rev Cancer. 2016 Aug 23;16(9):566-81
pubmed: 27550819
J Clin Oncol. 2018 Apr 10;36(11):1128-1139
pubmed: 29315015
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Blood. 2008 Mar 15;111(6):3220-4
pubmed: 18203952
J Immunother. 2004 Jul-Aug;27(4):317-27
pubmed: 15235393
J Immunother. 2008 Jun;31(5):500-5
pubmed: 18463534
Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004
pubmed: 25717386
J Biomed Res. 2014 Nov;28(6):468-75
pubmed: 25469116
Leuk Lymphoma. 2005 Mar;46(3):303-11
pubmed: 15621820
Cytometry B Clin Cytom. 2011 Mar;80(2):91-9
pubmed: 20809502
Blood. 2012 Mar 15;119(11):2644-56
pubmed: 22138512
J Clin Oncol. 2014 Mar 10;32(8):798-808
pubmed: 24344220
Clin Cancer Res. 2017 Nov 15;23(22):6982-6992
pubmed: 28912137
Mol Ther. 2018 Jul 5;26(7):1855-1866
pubmed: 29807781
PLoS One. 2014 Dec 03;9(12):e114345
pubmed: 25470820
Int J Cancer. 1997 Feb 7;70(4):375-82
pubmed: 9033642
Blood. 2002 Jun 15;99(12):4283-97
pubmed: 12036854
Blood. 2018 Sep 6;132(10):1022-1026
pubmed: 29925499
BMC Med. 2016 Oct 17;14(1):159
pubmed: 27745550
Blood. 2009 Jun 18;113(25):6392-402
pubmed: 19377047
J Clin Invest. 2012 Oct;122(10):3439-47
pubmed: 23023715
Blood. 1998 Apr 15;91(8):2925-34
pubmed: 9531603
Oncoimmunology. 2013 Oct 1;2(10):e26286
pubmed: 24353912
J Clin Oncol. 2016 Aug 10;34(23):2690-7
pubmed: 27069084
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167
pubmed: 31848460
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Blood Cancer J. 2017 Sep 8;7(9):e603
pubmed: 28885612
Blood. 2004 Mar 1;103(5):1755-62
pubmed: 14604957
N Engl J Med. 2010 Mar 11;362(10):875-85
pubmed: 20220182
Cancer Discov. 2017 Oct;7(10):1154-1167
pubmed: 28576927
Cancer Res. 2006 Jun 1;66(11):5716-22
pubmed: 16740709
Science. 2020 Feb 28;367(6481):
pubmed: 32029687
J Clin Oncol. 2020 Nov 10;38(32):3794-3804
pubmed: 32701411
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
J Clin Oncol. 2011 May 10;29(14):1812-26
pubmed: 21483001
Front Pharmacol. 2018 Oct 01;9:1118
pubmed: 30327605
Blood. 2019 Dec 5;134(23):2059-2069
pubmed: 31697809